Answers are grounded in this paper and cite their sources.
Case report shows complete response in a stage IV lung cancer patient treated with SL-28, suggesting promising therapy for advanced malignancies.
Background SL-28 (Leukocyte-Tells) is a novel cell therapy that uses allogeneic leukocytes whose anticancer activity is altered ex vivo through the recently discovered TezR receptors. We developed a method using TezR receptors, without direct genetic modification, to orchestrate leukocyte activity and generate so-called Leukocyte-Tells. Leukocyte-Tells are characterized by upregulated key pathways associated with immune cell function: migration, signaling, and enhanced energy metabolism, and demonstrate activity against various types of solid tumors (pancreatic cancer, prostate cancer, neuroblastoma). This study, for the first time, reports a complete response in a patient with stage IV-lung cancer with malignant pleural effusion treated with SL-28 (compassionate use NCT06872489). Case Presentation An 82-year-old male showed CT findings of a tumor in the right lower hilum with lesions measuring 18.3 × 16.7mm and 11.9 × 8.2mm; a 6.5 × 5.1mm lesion in the S3 segment of the right lung; and pleural effusion (2,700 mL). The patient received two cycles of chemotherapy (etoposide 100 mg/m², days 1-3, intravenously). A chest CT after two cycles showed no tumor response, with persistent pleural effusion exceeding 2,000 mL. SL-28 was cryopreserved and administered immediately after thawing at a dose of 1E7 to 1E8 cells/ injection once or twice-daily, five times/week. SL-28 therapy was well tolerated, with no graft-versus-host disease, cytokine-release-syndrome, or immune effector cell-associated neurotoxicity syndrome observed. After the first 3 weeks of therapy, CT demonstrated stable disease per RECIST1.1, with no growth of the S6 lesions and an 80% reduction of the S3 lesion (from 6.5 × 5.1mm to 4 × 2mm). At week 8, CT demonstrated a partial response per RECIST1.1: one lesion in S6 had completely resolved, the second showed a slight reduction (12 × 8mm to 11 × 7mm), and the lesion in S3 had completely resolved. The volume of pleural fluid gradually decreased to 50-100 mL. By week 22, no new nodules were observed, all S6 lesions had disappeared, and the remaining tumor in S3 was no longer visible. A fine-needle biopsy was performed at the original lesion site in S6, revealing no malignant cells, only fibrotic tissue. These findings, together with CT imaging, were consistent with a complete response per RECIST 1.1. The patient was monitored for an additional 6 months following completion of SL-28 therapy, with no evidence of disease recurrence. Conclusion SL-28 has demonstrated efficacy and safety in patient with stage IV lung cancer, supporting its potential as an “off-the-shelf” cell therapy for advanced malignancies. Similar results were obtained for patients with other solid tumors.
No takes yet. Share an insight, caveat, or question.
Tetz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: